Answers are grounded in this paper and cite their sources.
The identification of a novel series of small molecule BET inhibitors is described. Using crystallographic binding modes of an amino-isoxazole fragment and known BET inhibitors, a structure-based drug design effort lead to a novel isoxazole azepine scaffold. This scaffold showed good potency in biochemical and cellular assays and oral activity in an in vivo model of BET inhibition.
No takes yet. Share an insight, caveat, or question.
Gehling et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: